News

BIO-CAT, Inc. Celebrates 35 Years of Innovation, Growth, and Excellence in Enzymes and Probiotics

In 1988, Ed Schuler and his son, Chris Schuler, along with their business associate, Brian Huffman, embarked on a remarkable journey by founding BIO-CAT, Inc. in Keswick, Virginia. Operating out of Ed’s house and Brian’s barn, they began their venture with a single 20-kilogram blender, a few exhaust fans to control dust, and a small shed for warehousing and shipping. From the very start, their vision was clear: to provide exceptional customer service, deliver high-quality enzymes, and offer same-day or next-day shipping services – all with a focus on ensuring customer satisfaction. Notably, their commitment has endured over the years, with their first five customers still with the company today.

BIO-CAT quickly established itself as one of the pioneering distributors of dietary enzymes in the United States. They were trailblazers in developing enzyme formulations for use in digestive preparations. Their expertise in enzyme formulation and custom blending has led to the creation of an industry-leading range of products, from single-to multi-enzyme blends, to unique microbial solutions serving diverse markets, including human and animal probiotics, industrial, and agricultural sectors.

The company’s journey has been marked by significant milestones. After the first building was built in 1990, BIO-CAT quickly realized the need to expand and acquired the current 26-acre facility. The remainder of that decade witnessed BIO-CAT lead the way for new quality standards in the industry while doubling in size – from employee count to the size of the facility.

The Schuler family did not slow down in the 2000s. By 2004 they had added 40,000 additional sq. ft. to include refrigerated storage, established regulatory, quality and control teams, a new quality control lab, and become FDA registered. During that time, Chris Schuler also acquired a new company in Shakopee, Minnesota expanding into the high-growth microbial and probiotic segments. Operating as BIO-CAT Microbials, this vertically integrated fermentation site leads the market in Bacillus strain development and manufacturing.

In 2010 and 2011, BIO-CAT became the exclusive North American distributor of dietary supplement enzyme products for Amano Enzyme, Inc. and Shin Nihon Enzyme Co. – Japanese based world leaders in specialty enzymes. With access to both portfolios of specialty enzymes, BIO-CAT generated more growth which necessitated an additional 15,000 sq. ft. expansion in 2013.

BIO-CAT has continued to focus on growing their operations and scientific prowess in the industry. In 2021, BIO-CAT announced plans to expand its microbial fermentation production facility, and since 2022 the company has invested in 10 clinical studies, leading to publication in multiple prestigious journals, solidifying its position as an industry leader in innovation. This dedication to innovation has resulted in award-winning ingredients, such as OPTIZIOME® P3 HYDROLYZER™, and clinically substantiated probiotics, such as OPTIBIOME® BS50™.

Today, BIO-CAT continues to thrive, with Chris Schuler leading as CEO and President, and the next generation’s involvement is securing a path for unparalleled growth and innovation with third generation Stephen Schuler, who is spearheading the development of the new state-of-the-art probiotic fermentation facility in Virginia.

Under Chris’ leadership, the company has focused on core life sciences – supporting human, animal, and plant nutrition. “It’s amazing to see how far we have come, from our humble beginnings in a barn, to now having operations in Virginia and Minnesota. We are poised for further expansion with a second fermentation facility right here in Virginia. We have incredible customers on every continent and an extraordinary team of dedicated colleagues. We truly believe that the best is yet to come.”

 

Learn more here.

Recent News

04/23/2025

Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova’s board, and the successful completion of a new round of growth equity capital. These developments support Grenova’s strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories

04/22/2025

Phlow Corp. Expands Analytical Capabilities and Embraces Artificial Intelligence-Driven System, Ushering in a New Era of Modern Medicine Manufacturing in America

Phlow Corp., a leading pharmaceutical contract development and manufacturing organization (CDMO) in America, announced a significant expansion in its analytical capabilities, use of artificial intelligence (AI), workforce, and domestic infrastructure. Marking a period of exceptional growth and momentum, Phlow has more than doubled in size and now employs over 90+ highly skilled scientists and professionals

04/22/2025

ATCC Announces New Executive Leadership Appointments

ATCC, the world’s premier biological materials management and standards organization, today announced several new leadership appointments. Rebecca Bradford, MBA, has been promoted to the role of senior vice president of Government Programs, ATCC Federal Solutions (AFS); Manoj Menon, PhD, has joined the company as chief operating officer; and Rupali Lach was appointed vice president of Commercial Operations.